RYVU THERAPEUTICS ZY-,40/ PLSELVT00013 /
| 6/14/2024 3:39:22 PM | Chg. -0.420 | Volume | Bid10:00:01 PM | Ask10:00:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 11.320EUR | -3.58% | 0 Turnover: 0.000 |
-Bid Size: - | -Ask Size: - | 271.81 mill.EUR | - | - |
GlobeNewswire
12/11/2023
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Me...
GlobeNewswire
12/7/2023
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
GlobeNewswire
11/29/2023
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
10/23/2023
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Soli...
GlobeNewswire
10/4/2023
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2...
GlobeNewswire
9/13/2023
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
GlobeNewswire
6/25/2021
Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021
